Last reviewed · How we verify
Pf-07921585 (pf-07921585)
PF-07921585 is an investigational drug developed by Pfizer Inc. It is currently in clinical trials and has not yet received FDA approval. The drug is being evaluated for its potential in treating specific cancers. Its mechanism of action involves targeting a specific protein involved in tumor growth. While detailed safety data is limited, early trials have shown manageable side effects. Further studies are needed to fully understand its efficacy and safety profile.
At a glance
| Generic name | pf-07921585 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Small molecule inhibitor |
| Target | Specific protein involved in cancer cell proliferation |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | Not available |
Approved indications
- Indication not found
- Indication not found
Pipeline indications
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Pentobarbital
- Phenobarbital
- Rivaroxaban
- Apixaban
- Dabigatran
- Clopidogrel
- Ticagrelor
- Cilostazol
- Dipyridamole
- Eptifibatide
Key clinical trials
- A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pf-07921585 CI brief — competitive landscape report
- Pf-07921585 updates RSS · CI watch RSS
- Pfizer portfolio CI